Michael A Becker

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Michael A Becker
    University of Chicago Pritzker School of Medicine, Chicago, USA
    N Engl J Med 353:2450-61. 2005
  2. doi request reprint Update on emerging urate-lowering therapies
    Saima Chohan
    Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois, USA
    Curr Opin Rheumatol 21:143-9. 2009
  3. doi request reprint Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects
    Michael A Becker
    University of Chicago, Pritzker School of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Nucleosides Nucleotides Nucleic Acids 30:1011-7. 2011
  4. pmc Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
    Richard Furie
    Division of Rheumatology and Allergy Clinical Immunology, North Shore Long Island Jewish Health System, Marcus Avenue, Lake Success, New York 11042, USA
    Arthritis Res Ther 10:R109. 2008
  5. pmc The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
    Michael A Becker
    The University of Chicago Pritzker School of Medicine, MC0930, University of Chicago Medical Center, 5841 S, Maryland Avenue, Chicago, IL 60637, USA
    Arthritis Res Ther 12:R63. 2010
  6. doi request reprint Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout
    Michael A Becker
    University of Chicago Medical Center, Pritzker School of Medicine, 5841 S Maryland Ave, Chicago, IL 60637, USA
    J Rheumatol 36:1273-82. 2009
  7. doi request reprint Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
    Michael A Becker
    Rheumatology Section, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Nucleosides Nucleotides Nucleic Acids 27:585-91. 2008
  8. doi request reprint We can make gout management more successful now
    Michael A Becker
    Rheumatology Section, Department of Medicine, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Opin Rheumatol 20:167-72. 2008
  9. ncbi request reprint Hyperuricemia and associated diseases
    Michael A Becker
    Rheumatology Section, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Rheum Dis Clin North Am 32:275-93, v-vi. 2006
  10. ncbi request reprint Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
    Michael A Becker
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Arthritis Rheum 52:916-23. 2005

Research Grants

  1. C
    Michael Becker; Fiscal Year: 1993
  2. REGULATION OF PURINE NUCLEOTIDE SYNTHESIS IN HUMANS
    Michael Becker; Fiscal Year: 2001

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Michael A Becker
    University of Chicago Pritzker School of Medicine, Chicago, USA
    N Engl J Med 353:2450-61. 2005
    ..Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout...
  2. doi request reprint Update on emerging urate-lowering therapies
    Saima Chohan
    Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois, USA
    Curr Opin Rheumatol 21:143-9. 2009
    ..To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development...
  3. doi request reprint Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects
    Michael A Becker
    University of Chicago, Pritzker School of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Nucleosides Nucleotides Nucleic Acids 30:1011-7. 2011
    ....
  4. pmc Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
    Richard Furie
    Division of Rheumatology and Allergy Clinical Immunology, North Shore Long Island Jewish Health System, Marcus Avenue, Lake Success, New York 11042, USA
    Arthritis Res Ther 10:R109. 2008
    ....
  5. pmc The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
    Michael A Becker
    The University of Chicago Pritzker School of Medicine, MC0930, University of Chicago Medical Center, 5841 S, Maryland Avenue, Chicago, IL 60637, USA
    Arthritis Res Ther 12:R63. 2010
    ..The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial...
  6. doi request reprint Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout
    Michael A Becker
    University of Chicago Medical Center, Pritzker School of Medicine, 5841 S Maryland Ave, Chicago, IL 60637, USA
    J Rheumatol 36:1273-82. 2009
    ..To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout...
  7. doi request reprint Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
    Michael A Becker
    Rheumatology Section, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Nucleosides Nucleotides Nucleic Acids 27:585-91. 2008
    ..The complex relationship between urate-lowering and clinical outcome early in treatment has implications for both clinical and investigative approaches to urate-lowering management...
  8. doi request reprint We can make gout management more successful now
    Michael A Becker
    Rheumatology Section, Department of Medicine, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Opin Rheumatol 20:167-72. 2008
    ....
  9. ncbi request reprint Hyperuricemia and associated diseases
    Michael A Becker
    Rheumatology Section, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Rheum Dis Clin North Am 32:275-93, v-vi. 2006
    ..The issue of such a role remains unresolved and this article reviews the current status of the relationship between hyperuricemia and associated disorders...
  10. ncbi request reprint Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
    Michael A Becker
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Arthritis Rheum 52:916-23. 2005
    ..0 mg/dl)...
  11. doi request reprint Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol
    Saima Chohan
    University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Arthritis Care Res (Hoboken) 64:256-61. 2012
    ..To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout...
  12. doi request reprint Patient-reported outcomes in chronic gout: a report from OMERACT 10
    Jasvinder A Singh
    Medicine Service, Birmingham Veterans Affairs VA Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA
    J Rheumatol 38:1452-7. 2011
    ..To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
  13. doi request reprint Quality of life and disability in patients with treatment-failure gout
    Michael A Becker
    Division of Biological Sciences, Rheumatology Section, University of Chicago, Chicago, IL, USA
    J Rheumatol 36:1041-8. 2009
    ..The relationship between self-reported quality of life and disability and disease severity was evaluated in subjects with treatment-failure gout (n = 110) in a prospective, 52-week, observational study...
  14. ncbi request reprint What do I need to know about gout?
    Michael A Becker
    Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA
    J Fam Pract 59:S1-8. 2010
    ..In addition, most patients with gout eventually require long-term treatment with urate-lowering therapy (ULT) to reverse the chronic urate crystal deposition and to prevent recurrent flares that can cause permanent joint damage...
  15. ncbi request reprint Crystal-induced arthropathies: recent investigative advances
    Michael H Ellman
    University of Chicago, Pritzker School of Medicine, Rheumatology Section, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Curr Opin Rheumatol 18:249-55. 2006
    ..To highlight recent investigations that have stimulated renewed interest in crystal-induced arthropathies...
  16. ncbi request reprint Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
    Yasuhiro Takano
    Pharmaceutical Development Research Laboratories, Teijin Institute for Bio Medical Research, Teijin Pharma Limited, 4 3 2, Asahigaoka Hino, Tokyo 191 8512, Japan
    Life Sci 76:1835-47. 2005
    ..These results demonstrate that febuxostat is a potent non-purine, selective inhibitor of XO, and could be useful for the treatment of hyperuricemia and gout...
  17. pmc Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics
    Robert Terkeltaub
    San Diego VAMC Rheumatology Section, and University of California San Diego, La Jolla, California, USA
    Arthritis Res Ther 8:S4. 2006
    ..For this reason, our discussion focuses on the development of the novel xanthine oxidase inhibitor febuxostat and modified recombinant uricase preparations...
  18. ncbi request reprint Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman
    Pablo Garcia-Pavia
    La Paz University Hospital, Madrid, Spain
    Arthritis Rheum 48:2036-41. 2003
    ..This is the first reported instance of PRS overactivity in which the propositus and sole affected family member is a woman...
  19. ncbi request reprint Tophaceous gout: quantitative evaluation by direct physical measurement
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 32:2368-72. 2005
    ..This multicenter study assessed intra- and interrater reproducibility of a simple and direct physical measurement...
  20. doi request reprint Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial
    Mario H Cardiel
    Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
    Arthritis Rheum 58:2470-80. 2008
    ....
  21. ncbi request reprint Outcome evaluations in gout
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 34:1381-5. 2007
    ..Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed...

Research Grants16

  1. C
    Michael Becker; Fiscal Year: 1993
    ..5) Finally, genomic DNA libraries will be probed with hPRS cDNAs in order to clone and characterize normal and variant hPRS genes...
  2. REGULATION OF PURINE NUCLEOTIDE SYNTHESIS IN HUMANS
    Michael Becker; Fiscal Year: 2001
    ....